UBS Group
AIMT

UBS Group’s Aimmune Therapeutics AIMT Stock Holding History

UBS Group’s Portfolio AIMT Stock Details AIMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-45,000
Closed -$1.43M – 8402
2018
Q1 		$1.43M Buy
+45,000
New +$1.58M ﹤0.01% 3404

UBS Group's AIMT Position: Q4 2020 in Review

UBS Group sold out of Aimmune Therapeutics (AIMT) in Q4 2020, closing a stake of 99,157 shares — an estimated $3.42M sold.

UBS Group first reported a position in AIMT in Q3 2015 and held it in 21 quarters. The position peaked at $4.08M in Q1 2018. 0 funds tracked by Wall St. Rank hold AIMT as of Q4 2020.

  • UBS Group reported no remaining Aimmune Therapeutics position as of Q4 2020 after selling out during the quarter.
  • UBS Group sold 99,157 Aimmune Therapeutics shares in Q4 2020, an estimated $3.42M.
  • UBS Group first reported a position in Aimmune Therapeutics in Q3 2015 and held it in 21 quarters.
  • UBS Group's Aimmune Therapeutics position peaked at $4.08M in Q1 2018.
  • 0 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q4 2020.

Based on UBS Group's 13F filing for Q4 2020, filed 11 Feb 2021.